Troubled Biotechs Roundup: Avigen, Jazz, Alfacell, Panacos
This article was originally published in The Pink Sheet Daily
Executive Summary
Unlike other troubled biotechs, Avigen is not cash-poor; however, it is not advancing its small pipeline and its largest investor has called foul.
You may also be interested in...
Cash-Strapped Jazz Gets Stock Bump From Data On Fibromyalgia Candidate
Jazz Pharmaceuticals' stock price increased 39 percent on June 25, following the second announcement in a week of a successful Phase III trial for its fibromyalgia candidate, JZP-6 (sodium oxybate). The company's share price quickly retreated, dropping 56 cents on June 26 after analysts at Barclay's Capital downgraded the company because of concerns related to its financial health. Still the 21 percent increase in share value could position the specialty pharma to raise badly needed funds, given it has dwindling cash and defaulted on two recent quarterly interest payments on outstanding debt
Cash-Strapped Jazz Gets Stock Bump From Data On Fibromyalgia Candidate
Jazz Pharmaceuticals' stock price increased 39 percent on June 25, following the second announcement in a week of a successful Phase III trial for its fibromyalgia candidate, JZP-6 (sodium oxybate). The company's share price quickly retreated, dropping 56 cents on June 26 after analysts at Barclay's Capital downgraded the company because of concerns related to its financial health. Still the 21 percent increase in share value could position the specialty pharma to raise badly needed funds, given it has dwindling cash and defaulted on two recent quarterly interest payments on outstanding debt
CEO Quits Troubled Jazz, Hits The Road With Folk Singer Wife
As pharma struggles to make ends meet, spouse’s career takes off – and so does Samuel Saks